XML 24 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Q2 2021 Product Sales quarterly sequential analysis (Unreviewed)
 6 Months Ended
Jun. 30, 2021
Q2 2021 Product Sales quarterly sequential analysis (Unreviewed)  
Q2 2021 Product Sales quarterly sequential analysis (Unreviewed)

9)  Table 52: Q2 2021 - Product Sales quarterly sequential analysis (Unreviewed)76

The sequential quarterly information in respect of the three months ended 30 June 2021 included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Q1 2021

​

Q2 2021

​

    

​

​

​

Actual

​

CER

​

​

​

Actual

​

CER

​

​

​

$m

​

% change

​

% change

​

$m

​

% change

​

% change

Oncology

 

​

2,981 

​

 3

​

1 

​

3,286

​

10

​

11

Tagrisso

 

​

1,149

​

(1)

​

(3)

​

1,306

​

14

​

14

Imfinzi

 

​

556

​

-

​

(1)

​

604

​

9

​

10

Lynparza

 

​

543

​

9

​

8

​

588

​

8

​

9

Calquence

​

​

209

​

15

​

15

​

280

​

34

​

34

Koselugo

​

​

21

​

23

​

23

​

26

​

23

​

22

Enhertu

​

​

1

​

n/m

​

n/m

​

3

​

n/m

​

n/m

Zoladex*

 

​

221

​

2

​

-

​

244

​

10

​

11

Faslodex*

 

​

122

​

(6)

​

(8)

​

105

​

(14)

​

(12)

Iressa*

​

​

61

​

(9)

​

(11)

​

47

​

(23)

​

(22)

Arimidex*

​

​

44

​

22

​

18

​

29

​

(34)

​

(33)

Casodex*

 

​

42

​

7

​

5

​

41

​

(2)

​

(1)

Others

 

​

12

​

(4)

​

(6)

​

13

​

13

​

11

BioPharmaceuticals: CVRM

 

​

1,912

​

4

​

1

​

2,023

​

6

​

6

Farxiga

 

​

624

​

6

​

4

​

732

​

17

​

18

Brilinta

 

​

374

​

3

​

1

​

375

​

-

​

1

Bydureon

 

​

103

​

(16)

​

(17)

​

95

​

(8)

​

(7)

Onglyza

 

​

101

​

(3)

​

(6)

​

99

​

(2)

​

(2)

Byetta

 

​

16

​

(14)

​

(15)

​

16

​

(4)

​

(7)

Other diabetes

 

​

13

​

7

​

1

​

15

​

14

​

14

Lokelma

​

​

33

​

16

​

18

​

39

​

21

​

21

Roxadustat

 

​

39

​

n/m

​

n/m

​

51

​

32

​

32

Crestor*

 

​

274

​

(8)

​

(9)

​

265

​

(3)

​

(3)

Seloken/Toprol-XL*

 

​

250

​

25

​

21

​

266

​

6

​

7

Atacand*

 

​

34

​

(45)

​

(45)

​

23

​

(35)

​

(32)

Others

 

​

51

​

12

​

10

​

47

​

(7)

​

(10)

BioPharmaceuticals: Respiratory & Immunology

 

​

1,541

​

1

​

(1)

​

1,420

​

(8)

​

(7)

Symbicort

 

​

691

​

2

​

-

​

680

​

(2)

​

(1)

Pulmicort

 

​

330

​

(10)

​

(13)

​

167

​

(50)

​

(49)

Fasenra

 

​

260

​

(8)

​

(9)

​

320

​

23

​

23

Daliresp

 

​

60

​

11

​

10

​

54

​

(10)

​

(9)

Bevespi

 

​

13

​

7

​

8

​

13

​

1

​

3

Breztri

​

​

27

​

n/m

​

n/m

​

56

​

n/m

​

n/m

Others

 

​

160

​

28

​

25

​

130

​

(19)

​

(19)

Other medicines

 

​

548

​

(25)

​

(26)

​

454

​

(17)

​

(16)

Nexium*

 

​

403

​

7

​

5

​

336

​

(17)

​

(15)

Synagis*

 

​

24

​

(69)

​

(69)

​

24

​

1

​

1

Seroquel XR/IR*

 

​

29

​

51

​

38

​

21

​

(29)

​

(22)

Losec/Prilosec*

​

​

54

​

39

​

36

​

46

​

(14)

​

(15)

FluMist*

​

​

2

​

(99)

​

(99)

​

1

​

(51)

​

(71)

Others

​

​

36

​

(6)

​

(4)

​

26

​

(28)

​

(32)

COVID-19

 

​

275

​

n/m

​

n/m

​

862

​

n/m

​

n/m

Pandemic COVID-19 vaccine

 

​

275

​

n/m

​

n/m

​

862

​

n/m

​

n/m

Total Product Sales

​

​

7,257

​

4

​

1

​

8,045

​

11

​

12

76 The table provides an analysis of sequential quarterly Product Sales, with Actual and CER growth rates reflecting quarter-on-quarter growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. *Denotes a legacy medicine.